<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164826</url>
  </required_header>
  <id_info>
    <org_study_id>P-605/06-00</org_study_id>
    <nct_id>NCT01164826</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  To Assess the bioequivalence study of Nabumetone 750 mg tablets and Relafen® 750 mg&#xD;
           tablets in healthy, adult, human subjects under fed conditions with a washout period of&#xD;
           16 days.&#xD;
&#xD;
        -  To monitor adverse events and ensure the safety of subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, two treatment, two period, two sequence, single dose crossover,&#xD;
      bioequivalence study of nabumetone 750 mg tablets of Dr. Reddy's Laboratories Limited and&#xD;
      Relafen® 750 mg tablets of Glaxosmithkline research triangle park, in healthy, adult, human&#xD;
      subjects under fed conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study is based on Cmax and AUC parameters</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nabumetone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relafen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabumetone</intervention_name>
    <description>Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Nabumetone</arm_group_label>
    <other_name>Relafen® 750 mg Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relafen</intervention_name>
    <description>Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.</description>
    <arm_group_label>Relafen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following criteria to be considered for inclusion into&#xD;
        this study:&#xD;
&#xD;
          -  Subjects who will provide written informed consent&#xD;
&#xD;
          -  Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing&#xD;
             at least 50 kg.&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as&#xD;
             weight in Kg/height in m2&#xD;
&#xD;
          -  Subjects must be of normal health, as determined by medical history and physical&#xD;
             examination performed within 21 days prior to the commencement of the study.&#xD;
&#xD;
          -  Subjects whose screening laboratory values are within normal limits or considered by&#xD;
             the physician/investigator to be of no clinical significance.&#xD;
&#xD;
          -  Have normal ECG, X-ray and vital signs.&#xD;
&#xD;
          -  Availability of the subject for the entire study period and willingness to adhere to&#xD;
             the protocol requirements as evidenced by written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subjects will be excluded based on the following criteria:&#xD;
&#xD;
          -  Subjects incapable of understanding the informed consent.&#xD;
&#xD;
          -  Subjects who have:&#xD;
&#xD;
               1. Systolic blood pressure less than 90 mm of Hg and more than 140 mm of Hg&#xD;
&#xD;
               2. Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor&#xD;
                  deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the&#xD;
                  physician/investigator.&#xD;
&#xD;
               3. Pulse rate below SO/min and above lOO/min.&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to Nabumetone or any other&#xD;
             related drugs.&#xD;
&#xD;
          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal&#xD;
             function.&#xD;
&#xD;
          -  Clinically significant illness within 4 weeks before the start of the study.&#xD;
&#xD;
          -  Consumption of grapefruit for the past ten days prior to the dosing day until the&#xD;
             completion of the study.&#xD;
&#xD;
          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has&#xD;
             difficulty in abstaining from smoking from 48 hours before dosing and until the&#xD;
             completion of the study.&#xD;
&#xD;
          -  Subjects who has taken over the counter or prescribed medications for during the last7&#xD;
             days from the date of study.&#xD;
&#xD;
          -  Subjects should not have taken enzyme modifying drugs or any systemic medication&#xD;
             within the past 30 days prior to start of clinical study&#xD;
&#xD;
          -  History of any psychiatric illness, which may impair the ability to provide written,&#xD;
             informed consent.&#xD;
&#xD;
          -  Subjects with clinically significant abnormal values of laboratory parameters.&#xD;
&#xD;
          -  Subjects who have participated in any other clinical investigation using experimental&#xD;
             drug or had bled more than 330 rnL in the past 90 days before the date of start of&#xD;
             study.&#xD;
&#xD;
          -  Subjects with positive screen for drugs of abuse and alcohol.&#xD;
&#xD;
          -  Any subject in whom Nabumetone is contraindicated for medical reasons.&#xD;
&#xD;
          -  Any subject with recent history of surgery.&#xD;
&#xD;
          -  A history of difficulty in donating blood.&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen, anti HCV and Anti&#xD;
             HAV antibodies&#xD;
&#xD;
          -  A positive test result for HIV antibody and/or syphilis&#xD;
&#xD;
          -  A recent history or presence of asthma (including aspirin induced asthma) or nasa&#xD;
             polyp.&#xD;
&#xD;
          -  A recent history of alcoholism &lt; 2 years) or of moderate (180 mL/day) alcohol use,or&#xD;
             consumption of alcohol within 48 hr prior to receiving Investigational Product.&#xD;
&#xD;
          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the Investigational Product and throughout the subjects participation in the&#xD;
             study. In any such case subject selection will be at the discretion of the&#xD;
             Investigator / Medical expert.&#xD;
&#xD;
          -  Female subjects who are pregnant or who are able (women with child bearing potential)&#xD;
             to become pregnant during the study will not be allowed to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Mohan lal Siva Prasad Sayana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Pvt. Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. M.S. Mohan/ Vice President - R &amp; D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Nabumetone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabumetone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

